e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Emerging strategies for airway disease treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD
Srinivasa Honnegowda (Navi Mumbai, India), Srinivasa Honnegowda, Abraham Thomas, Sachin Chaudhari, Sanjib Das, Daisy Shah, Malini Bajpai, Indrani Sarkar, Abhay Kulkarni, Girish Gudi, Satyawan Jadhav, Neelima Khairatkar-Joshi
Source:
International Congress 2015 – Emerging strategies for airway disease treatments
Session:
Emerging strategies for airway disease treatments
Session type:
Thematic Poster Session
Number:
4367
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Srinivasa Honnegowda (Navi Mumbai, India), Srinivasa Honnegowda, Abraham Thomas, Sachin Chaudhari, Sanjib Das, Daisy Shah, Malini Bajpai, Indrani Sarkar, Abhay Kulkarni, Girish Gudi, Satyawan Jadhav, Neelima Khairatkar-Joshi. LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD. Eur Respir J 2015; 46: Suppl. 59, 4367
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
MUC1-CT mediates corticosteroid responses in COPD
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
The mechanisms of antiinflammatory effect of mucolytic therapy
Source: International Congress 2014 – Predictors
Year: 2014
LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Additive effect of targeted lung denervation plus drug in patients with COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept